ERAP2 Inhibitors

Chemical inhibitors of ERAP2 can obstruct its function by various mechanisms, primarily by binding to its active site, which is essential for the enzyme's aminopeptidase activity responsible for trimming peptides. DG013A, for instance, binds directly to the active site of ERAP2, effectively preventing the protein from processing antigenic peptides. Similarly, L-Leucinethiol and Bestatin function as competitive inhibitors, occupying the active site of ERAP2 and thereby hindering the cleavage of peptide substrates. Amastatin operates in a comparable manner, attaching itself to the active site and impeding ERAP2's ability to trim peptides. These inhibitors essentially mimic the structure of the substrates or the transition state of peptide hydrolysis, thereby blocking the catalytic function of ERAP2.

PAQ-22 and KYP-2047 also target the active site of ERAP2 but may do so with a selectivity that could provide a more nuanced inhibition, specifically tailoring the interaction to the unique aspects of ERAP2's peptide-binding domain. PL-1 acts in a similar vein, selectively binding to the active site and preventing the aminopeptidase activity of ERAP2. JMV-390-1 takes a slightly different approach by targeting the zinc-binding motif that is pivotal for ERAP2's enzymatic activity. CHR-2863 and Actinonin, on the other hand, interfere with the catalytic site of ERAP2: CHR-2863 through direct interaction and Actinonin by mimicking the transition state, which effectively blocks the enzyme's active site. GLPG-0778 and KB-R7785 round out the list of inhibitors by binding competitively to the active site, ensuring that ERAP2 is unable to perform its role in editing peptides, which is a crucial step in the immune response process.